CD47/SIRPα axis: bridging innate and adaptive immunity
Myeloid immune cells are frequently present in the tumor environment, and although they can positively contribute to tumor control they often negatively impact anticancer immune responses. One way of inhibiting the positive contributions of myeloid cells is by signaling through the cluster of differ...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/7/e004589.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864105347317760 |
|---|---|
| author | Sjoerd H van der Burg Anneloes van Duijn Ferenc A Scheeren |
| author_facet | Sjoerd H van der Burg Anneloes van Duijn Ferenc A Scheeren |
| author_sort | Sjoerd H van der Burg |
| collection | DOAJ |
| description | Myeloid immune cells are frequently present in the tumor environment, and although they can positively contribute to tumor control they often negatively impact anticancer immune responses. One way of inhibiting the positive contributions of myeloid cells is by signaling through the cluster of differentiation 47 (CD47)/signal regulatory protein alpha (SIRPα) axis. The SIRPα receptor is expressed on myeloid cells and is an inhibitory immune receptor that, upon binding to CD47 protein, delivers a ‘don’t eat me’ signal. As CD47 is often overexpressed on cancer cells, treatments targeting CD47/SIRPα have been under active investigation and are currently being tested in clinical settings. Interestingly, the CD47/SIRPα axis is also involved in T cell-mediated antitumor responses. In this perspective we provide an overview of recent studies showing how therapeutic blockade of the CD47/SIRPα axis improves the adaptive immune response. Furthermore, we discuss the interconnection between the myeloid CD47/SIRPα axis and adaptive T cell responses as well as the potential therapeutic role of the CD47/SIRPα axis in tumors with acquired resistance to the classic immunotherapy through major histocompatibility complex downregulation. Altogether this review provides a profound insight for the optimal exploitation of CD47/SIRPα immune checkpoint therapy. |
| format | Article |
| id | doaj-art-9e5b433f0e75451db7985f05e309a250 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-9e5b433f0e75451db7985f05e309a2502025-02-09T07:10:13ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-07-0110710.1136/jitc-2022-004589CD47/SIRPα axis: bridging innate and adaptive immunitySjoerd H van der Burg0Anneloes van Duijn1Ferenc A Scheeren2Oncode Institute, Utrecht, The NetherlandsDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Dermatology, Leiden University Medical Center, Leiden, The NetherlandsMyeloid immune cells are frequently present in the tumor environment, and although they can positively contribute to tumor control they often negatively impact anticancer immune responses. One way of inhibiting the positive contributions of myeloid cells is by signaling through the cluster of differentiation 47 (CD47)/signal regulatory protein alpha (SIRPα) axis. The SIRPα receptor is expressed on myeloid cells and is an inhibitory immune receptor that, upon binding to CD47 protein, delivers a ‘don’t eat me’ signal. As CD47 is often overexpressed on cancer cells, treatments targeting CD47/SIRPα have been under active investigation and are currently being tested in clinical settings. Interestingly, the CD47/SIRPα axis is also involved in T cell-mediated antitumor responses. In this perspective we provide an overview of recent studies showing how therapeutic blockade of the CD47/SIRPα axis improves the adaptive immune response. Furthermore, we discuss the interconnection between the myeloid CD47/SIRPα axis and adaptive T cell responses as well as the potential therapeutic role of the CD47/SIRPα axis in tumors with acquired resistance to the classic immunotherapy through major histocompatibility complex downregulation. Altogether this review provides a profound insight for the optimal exploitation of CD47/SIRPα immune checkpoint therapy.https://jitc.bmj.com/content/10/7/e004589.full |
| spellingShingle | Sjoerd H van der Burg Anneloes van Duijn Ferenc A Scheeren CD47/SIRPα axis: bridging innate and adaptive immunity Journal for ImmunoTherapy of Cancer |
| title | CD47/SIRPα axis: bridging innate and adaptive immunity |
| title_full | CD47/SIRPα axis: bridging innate and adaptive immunity |
| title_fullStr | CD47/SIRPα axis: bridging innate and adaptive immunity |
| title_full_unstemmed | CD47/SIRPα axis: bridging innate and adaptive immunity |
| title_short | CD47/SIRPα axis: bridging innate and adaptive immunity |
| title_sort | cd47 sirpα axis bridging innate and adaptive immunity |
| url | https://jitc.bmj.com/content/10/7/e004589.full |
| work_keys_str_mv | AT sjoerdhvanderburg cd47sirpaaxisbridginginnateandadaptiveimmunity AT anneloesvanduijn cd47sirpaaxisbridginginnateandadaptiveimmunity AT ferencascheeren cd47sirpaaxisbridginginnateandadaptiveimmunity |